Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of 0.25, 0.5, 1, 2, 4, 20, 50, 100, 150 and 200 mg BI 60732 Powder in Bottle (PIB) Administered to Healthy Male Volunteers in a Randomised, Double Blind, Placebo Controlled Phase I Trial

NCT02244203 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02244203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02244203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of 0.25, 0.5, 1, 2, 4, 20, 50, 100, 150 and 200 mg BI 60732 Powder in Bottle (PIB) Administered to Healthy Male Volunteers in a Randomised, Double Blind, Placebo Controlled Phase I Trial
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2009
Completion date
Not reported
Enrollment
56 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy